Moleculin Biotech, Inc. (MBRX): Total Liabilities
$7.12M
As of 2025-12-31
$9.50M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.12M | +24.5% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $5.72M | n/c | 2026-03-18, Balance as of period end |
| 2023-12-31 | $12.14M | +132.2% | 2025-03-21, Balance as of period end |
| 2022-12-31 | $5.23M | +2.6% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $5.10M | -54.8% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $11.27M | +16.6% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $9.66M | +81.9% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $5.31M | +124.7% | 2020-03-19, Balance as of period end |
| 2017-12-31 | $2.37M | +65.0% | 2019-02-21, Balance as of period end |
| 2016-12-31 | $1.43M | +85.4% | 2018-03-28, Balance as of period end |
| 2015-12-31 | $772.8K | n/a | 2017-04-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $7.12M | +24.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare MBRX, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗